HCM - Hutchmed grants exclusive license to Inmagene for two drug candidates
2024-02-02 10:25:36 ET
More on Hutchison China MediTech
- HUTCHMED Deserves An Upgrade After U.S. FDA Approval Of Cancer Drug
- Chinese regulators accept HUTCHMED application for solveplenib
- Hutchmed upgraded at Deutsche Bank; cancer drug approval cited
- Seeking Alpha’s Quant Rating on Hutchison China MediTech
- Historical earnings data for Hutchison China MediTech